In patients with impaired glucose tolerance or T2D, pioglitazone reduced carotid IMT (306, 307) and atherosclerotic plaque inflammation in association with decreased CRP and increased HDL-cholesterol (308, 309). Here, CRP is linked to type 2 diabetes mellitus.